CY1116183T1 - Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης - Google Patents

Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης

Info

Publication number
CY1116183T1
CY1116183T1 CY20151100339T CY151100339T CY1116183T1 CY 1116183 T1 CY1116183 T1 CY 1116183T1 CY 20151100339 T CY20151100339 T CY 20151100339T CY 151100339 T CY151100339 T CY 151100339T CY 1116183 T1 CY1116183 T1 CY 1116183T1
Authority
CY
Cyprus
Prior art keywords
antagonists
piperazinoidions
oxytocin receptors
pyridyl
dimethyl
Prior art date
Application number
CY20151100339T
Other languages
English (en)
Inventor
Alan David Borthwick
Deirdre Mary Bernadette Hickey
John Liddle
Andrew Mcmurtrie Mason
Original Assignee
Glaxo Group Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32800053&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1116183(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Limited filed Critical Glaxo Group Limited
Publication of CY1116183T1 publication Critical patent/CY1116183T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Περιγράφονται ενώσεις του τύπου (I) όπου R1 είναι 2-ινδανύλ, R2 είναι 1-μεθυλπροπύλ, R3 είναι ομάδα επιλεγόμενη από 2,6-διμεθυλ-3-πυριδύλ ή 4,6-διμεθυλ-3-πυριδύλ, R4 αντιπροσωπεύει μεθύλ και R5 αντιπροσωπεύει υδρογόνο ή μεθύλ ή R4 και R5 μαζί με το άτομο αζώτου προς το οποίο συνδέονται αντιπροσωπεύουν μορφολίνο και φαρμακευτικώς αποδεκτά παράγωγα αυτών, όπως μέθοδοι για παρασκευή αυτών, φαρμακευτικές συνθέσεις που περιέχουν αυτές και χρήση αυτών στην ιατρική, ιδιαιτέρως χρήση αυτών ως ανταγωνιστές οξυτοκίνης.
CY20151100339T 2004-06-23 2015-04-08 Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης CY1116183T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0414093.5A GB0414093D0 (en) 2004-06-23 2004-06-23 Novel compounds
EP05755563.3A EP1758886B1 (en) 2004-06-23 2005-06-21 Piperazinediones as oxytocin receptor antagonists

Publications (1)

Publication Number Publication Date
CY1116183T1 true CY1116183T1 (el) 2017-02-08

Family

ID=32800053

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20151100339T CY1116183T1 (el) 2004-06-23 2015-04-08 Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης

Country Status (30)

Country Link
US (9) US7550462B2 (el)
EP (2) EP2918580A1 (el)
JP (2) JP5405019B2 (el)
KR (1) KR101186447B1 (el)
CN (1) CN1972924B (el)
AR (1) AR049405A1 (el)
AU (1) AU2005256470B2 (el)
BR (1) BRPI0512376A (el)
CA (1) CA2571527C (el)
CY (1) CY1116183T1 (el)
DK (1) DK1758886T3 (el)
ES (1) ES2537801T3 (el)
GB (1) GB0414093D0 (el)
HK (2) HK1106499A1 (el)
HR (1) HRP20150401T1 (el)
HU (1) HUE025869T2 (el)
IL (2) IL179905A0 (el)
MA (1) MA28675B1 (el)
MX (1) MXPA06014545A (el)
MY (1) MY143578A (el)
NO (1) NO338769B1 (el)
NZ (1) NZ551733A (el)
PE (1) PE20060477A1 (el)
PL (1) PL1758886T3 (el)
PT (1) PT1758886E (el)
RU (1) RU2382038C2 (el)
SI (1) SI1758886T1 (el)
TW (1) TWI348466B (el)
WO (1) WO2006000399A1 (el)
ZA (1) ZA200610022B (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0130677D0 (en) 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
ES2397327T3 (es) 2002-06-17 2013-03-06 Thrasos, Inc. Compuestos asociados a un dominio único de TDF y análogos de los mismos
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
EP2789342A1 (en) 2004-06-17 2014-10-15 Thrasos Innovation, Inc. TDF-related compounds and analogs thereof
GB0414093D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414100D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
SI2497780T1 (sl) 2005-09-20 2015-08-31 Thrasos Innovation, Inc. Spojine, povezane s TDF, in njihovi analogi
JP2013509391A (ja) 2009-10-30 2013-03-14 グラクソ グループ リミテッド （３ｒ，６ｒ）−３−（２，３−ジヒドロ−１ｈ−インデン−２−イル）−１−［（１ｒ）−１−（２，６−ジメチル−３−ピリジニル）−２−（４−モルホリニル）−２−オキソエチル］−６−［（１ｓ）−１−メチルプロピル］−２，５−ピペラジンジオンの新規結晶性形態
HUE058872T2 (hu) 2016-01-04 2022-09-28 ObsEva SA Hidroxipropil-tiazolidin-karboxamid származék alfa-amino-észtere és tokolitikus szer együttes alkalmazása
WO2017203012A1 (en) * 2016-05-27 2017-11-30 Glaxosmithkline Intellectual Property (No.2) Limited Epelsiban for use in the treatment of adenomyosis
EP3487493B1 (en) 2016-07-21 2021-09-01 ObsEva S.A. Oxytocin antagonist dosing regimens for promoting embryo implantation and preventing miscarriage
RU2762019C1 (ru) * 2018-05-29 2021-12-14 Као Корпорейшн Способ оценки функциональной способности листа вызывать ощущение комфорта и лист, вызывающий ощущение комфорта
JP2022546716A (ja) 2019-09-03 2022-11-07 オブセヴァ エス．エー． 胚着床を促進し、流産を防止するためのオキシトシンアンタゴニスト投与レジメン
CA3167121A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596819A (en) * 1984-01-23 1986-06-24 Warner-Lambert Company Modified tripeptides
DE3830096A1 (de) 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
US5817751A (en) * 1994-06-23 1998-10-06 Affymax Technologies N.V. Method for synthesis of diketopiperazine and diketomorpholine derivatives
GB2326639A (en) 1997-06-18 1998-12-30 Merck & Co Inc Piperazine Oxytocin Receptor Antagonists
KR20010034442A (ko) 1998-01-27 2001-04-25 아벤티스 파마슈티칼즈 프로덕츠 인코포레이티드 치환된 옥소아자헤테로사이클릴 인자 Ｘａ 억제제
WO1999038844A1 (en) 1998-01-29 1999-08-05 Aventis Pharmaceuticals Products Inc. Method for preparing an n-[(aliphatic or aromatic)carbonyl]-2-aminoacetamide compound and a cyclyzed compound
WO1999047549A1 (en) * 1998-03-16 1999-09-23 Ontogen Corporation PIPERAZINES AS INHIBITORS OF FRUCTOSE-1,6-BISPHOSPHATASE (FBPase)
GB0130677D0 (en) * 2001-12-21 2002-02-06 Glaxo Group Ltd Medicaments and novel compounds
GB0314738D0 (en) * 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
GB0314733D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Medicaments
GB0414093D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414092D0 (en) * 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0414100D0 (en) 2004-06-23 2004-07-28 Glaxo Group Ltd Novel compounds
GB0428235D0 (en) 2004-12-23 2005-01-26 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
BRPI0512376A (pt) 2008-03-11
US20070254888A1 (en) 2007-11-01
US8202864B2 (en) 2012-06-19
US20110152262A1 (en) 2011-06-23
US20100305127A1 (en) 2010-12-02
US20120202811A1 (en) 2012-08-09
CN1972924A (zh) 2007-05-30
SI1758886T1 (sl) 2015-06-30
HRP20150401T1 (hr) 2015-05-08
EP2918580A1 (en) 2015-09-16
EP1758886A1 (en) 2007-03-07
AR049405A1 (es) 2006-07-26
IL237513A0 (en) 2015-04-30
KR101186447B1 (ko) 2012-09-27
JP5405019B2 (ja) 2014-02-05
MA28675B1 (fr) 2007-06-01
AU2005256470A1 (en) 2006-01-05
US7550462B2 (en) 2009-06-23
DK1758886T3 (da) 2015-04-27
CA2571527C (en) 2013-02-26
EP1758886B1 (en) 2015-03-04
TW200616636A (en) 2006-06-01
MY143578A (en) 2011-05-31
US7919492B2 (en) 2011-04-05
PT1758886E (pt) 2015-04-22
NO338769B1 (no) 2016-10-17
PL1758886T3 (pl) 2015-08-31
US20150157640A1 (en) 2015-06-11
US20090247541A1 (en) 2009-10-01
JP2008503534A (ja) 2008-02-07
GB0414093D0 (en) 2004-07-28
IL179905A0 (en) 2007-05-15
JP2013010790A (ja) 2013-01-17
MXPA06014545A (es) 2007-03-12
AU2005256470B2 (en) 2012-02-02
US9408851B2 (en) 2016-08-09
PE20060477A1 (es) 2006-08-24
JP5503709B2 (ja) 2014-05-28
HK1208669A1 (en) 2016-03-11
US20140235639A1 (en) 2014-08-21
TWI348466B (en) 2011-09-11
WO2006000399A1 (en) 2006-01-05
RU2382038C2 (ru) 2010-02-20
US8742099B2 (en) 2014-06-03
NZ551733A (en) 2010-06-25
CA2571527A1 (en) 2006-01-05
RU2007102274A (ru) 2008-07-27
KR20070031953A (ko) 2007-03-20
ES2537801T3 (es) 2015-06-12
NO20070173L (no) 2007-01-22
ZA200610022B (en) 2008-07-30
HUE025869T2 (en) 2016-05-30
CN1972924B (zh) 2011-07-20
HK1106499A1 (en) 2008-03-14
US20160030442A1 (en) 2016-02-04
US20130253188A1 (en) 2013-09-26

Similar Documents

Publication Publication Date Title
CY1116183T1 (el) Πιπεραζινοδιονες ως ανταγωνιστες υποδοχεα οξυτοκινης
CY1106679T1 (el) Αζαδικυκλικες ετεροκυκλικες ενωσεις ως τροποποιητες κανναβινοειδους υποδοχεα
AR012315A1 (es) Derivados de ditiolan y el uso de los mismos en la fabricacion de un medicamento.
PE20090816A1 (es) Derivados de pirrolopirimidinona como agentes ligandos de los receptores p2x3
HUP0402313A2 (hu) Szerotonin újrafelvételt gátló fenilpiperazin-származékok, az ezeket tartalmazó gyógyászati készítmények és alkalmazásuk
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
AR055878A1 (es) Derivados de ciclopropanocarboxamida
CY1109656T1 (el) Υποκατεστημενα παραγωγα μορφολινης και θειομορφολινης
CY1107677T1 (el) Παραγωγα της 1-[indol-3-yl)carbonyl]piperazine
MXPA05011710A (es) Derivados de pirimidina con actividad de crf.
CY1110332T1 (el) Παραγωγα βενζιμιδαζολης, συνθεσεις που τα περιεχουν, παρασκευη αυτων και χρηση τους
AR035153A1 (es) Derivados de carboxamidas y cetonas de dihidrobenzodioxina
CY1107703T1 (el) Υποκατεστημενες δικετοπιπεραζινες και χρηση αυτων ως ανταγωνιστες οξυτοκινης
NO20025641D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
PA8495101A1 (es) Derivados de 13-metileritromicina
EA200700901A1 (ru) Производные 2-амидо-4-фенилтиазола, их получение и применение в терапии
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
ECSP088829A (es) Derivados de bencimidazol 5-sulfonamida como ligandos del receptor cannabinoide 1 (cb1)
NO20025640D0 (no) Substituerte 1-aminoalkyl-laktamer og deres anvendelse som muscarin-reseptor-antagonister
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
CL2003002565A1 (es) Compuestos derivados de 3h-quinazolin-4-ona, su proceso de preparacion, composicion farmaceutica que los contiene, y uso en el tratamiento y prevencion de enfermedades mediadas por inhibidores de mao-b, tales como la enfermedad de alzheimer y demenci
TW200616635A (en) Novel compounds
CY1112218T1 (el) Νεα παραγωγα ανταγωνιστες υποδοχεα βιτρονεκτινης, μεθοδος παρασκευης τους, η εφαρμογη τους ως φαρμακα και φαρμακευτικες συνθεσεις που τα περιεχουν
AR027454A1 (es) Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos